





## **Biosafety Clearing-House (BCH)**

| mation  | LAST UPDATED: 05 SEP 20  |
|---|--|
|   |  |
| PARTY TO THE CARTAGENA PROTOCOL ON BIOSAFETY                                | ENTRY INTO FORCE: 28 MAY 2009  |
| /stakeholders who were consulted or participated in the p                   | preparation of this report   |
| ORATORY OF MINISTRY OF AGRICULTURE  | EN   |
| covered by this report  |  |
|   |  |
|   |  |
|   |  |
| ntry a Party to the Cartagena Protocol on Biosafety (CPB                    |  |
|   | EN   |
| eneral provisions   |  |
| •   |  |
| ountry introduced the necessary legal, administrative an n of the Protocol? | d other measures for the   |
|   | nd other measures for the  |
|   | PARTY TO THE CARTAGENA PROTOCOL ON BIOSAFETY  //Stakeholders who were consulted or participated in the ORATORY OF MINISTRY OF AGRICULTURE  covered by this report  Cartagena Protocol on Biosafety  ntry a Party to the Cartagena Protocol on Biosafety (CPB |

| 7. Has your country established a mechanism for the budgetary allocations of funds for the operates national biosafety framework?  | ion o  |
|--|--------|
| Yes  | EN     |
| .8. Does your country have permanent staff to administer functions directly related to the national biosafety framework?   |        |
| Yes  | EN     |
| .9. If you answered Yes to question 18, how many permanent staff members are in place whose fur<br>are directly related to the national biosafety framework?   | nction |
| Less than 5  | EN     |
| 20. Has your country's biosafety framework / laws / regulations / guidelines been submitted to the Biosafety Clearing-House (BCH)?   |        |
| Partially  | EN     |
| 21. Here you may provide further details on the implementation of Article 2 in your country  |        |
| We have a Law Proposal that covers the management of the Modified Living Organisms submitted to the National Assembly of the Republic for approval. The same proposal is based solely on the Protocol. | EN     |
| rticle 5 - Pharmaceuticals   |        |
| 22. Does your country regulate the transboundary movement, handling and use of living modified organisms (LMOs) which are pharmaceuticals?   |        |
| No   | EN     |
| 3. If you answered Yes to question 22, has this information been submitted to the BCH?   |        |
| 24. Here you may provide further details on the implementation of Article 5 in your country:   |        |
|  |        |

| 25. Does your country regulate the transit of LMOs?  |  |
|--|--|
| No   | EN   |
| NO   | LI   |
| 26. Does your country regulate the contained use of LMOs?  |  |
| No   | EN   |
| 27. If you answered Yes to questions 25 or 26, has this information  | n been submitted to the BCH?   |
| 28. Here you may provide further details on the implementation o   | f Article 6 in your country:   |
| NOT APPLICABLE YET   | EN   |
|  |  |
| 29. Has your country adopted law(s) / regulations / administrative   | measures for the operation of the AIA  |
| procedure of the Protocol OR a domestic regulatory framework co  | nsistent with the Protocol regarding th  |
| procedure of the Protocol OR a domestic regulatory framework co  | nsistent with the Protocol regarding the the environment?  |
| orocedure of the Protocol OR a domestic regulatory framework contransboundary movement of LMOs for intentional introduction into  No  30. Has your country established a mechanism for taking decision   | nsistent with the Protocol regarding the the environment?  EN  s regarding first intentional   |
| orocedure of the Protocol OR a domestic regulatory framework contransboundary movement of LMOs for intentional introduction into  No  30. Has your country established a mechanism for taking decision   | nsistent with the Protocol regarding the the environment?  EN  s regarding first intentional to the environment?   |
| No  Solution and the Protocol OR a domestic regulatory framework contransboundary movement of LMOs for intentional introduction into No  Solution No  Solution and the Protocol OR a domestic regulatory framework contransboundary movement of LMOs for intentional introduction into No  Solution | resistent with the Protocol regarding the othe environment?  EN  s regarding first intentional to the environment?  EN  apply to cases of intentional introduct  |
| 30. Has your country established a mechanism for taking decision ransboundary movements of LMOs for intentional introduction int   | resistent with the Protocol regarding the othe environment?  EN  Is regarding first intentional to the environment?  EN  EN  apply to cases of intentional introduct ary movement?  under its jurisdiction to notify in writing the environment of the environment o |
| No  30. Has your country established a mechanism for taking decision into the modern answered Yes to question 30, does the mechanism also of LMOs into the environment that were not subject to transbound 32. Has your country established legal requirements for exporters the competent national authority of the Party of import prior to the  | resistent with the Protocol regarding the othe environment?  EN  Is regarding first intentional to the environment?  EN  EN  apply to cases of intentional introduct ary movement?  under its jurisdiction to notify in writing the environment of the environment o |
| No  30. Has your country established a mechanism for taking decision transboundary movements of LMOs for intentional introduction into No  31. If you answered Yes to question 30, does the mechanism also of LMOs into the environment that were not subject to transboundary. Calculate the competent national authority of the Party of import prior to the of an LMO that falls within the scope of the AIA procedure?   | s regarding first intentional to the environment?  EN  apply to cases of intentional introduct ary movement?  under its jurisdiction to notify in writing intentional transboundary movement  EN   |

| No   | EN   |
|--|--|
| 35. Has your country ever taken a decision on an application / notification regatransboundary movements of LMOs for intentional introduction into the enviro   | _  |
| No   | EN   |
| 36. If you answered Yes to question 35, how many LMOs has your country applintentional introduction into the environment?  | roved to date for import for   |
| 37. If you answered Yes to question 35, how many LMOs, not imported, has yo  | ur country approved to date  |
| 88. In the current reporting period, how many applications/notifications has yo<br>regarding intentional transboundary movements of LMOs for intentional introd  | •  |
| None   | EN   |
|  |  |
| 39. In the current reporting period, how many decisions has your country taked transboundary movements of LMOs for intentional introduction into the enviro  |  |
| None  10. With reference to the decisions taken on intentional transboundary movemntroduction into the environment, has your country received a notification from  | ents of LMOs for intentiona  |
| ransboundary movements of LMOs for intentional introduction into the enviro  | nment?  EN  Dents of LMOs for intentional ments of export of the Party(ies) of export of the Party(ies).   |
| None  10. With reference to the decisions taken on intentional transboundary movement of the environment, has your country received a notification from the exporter(s) prior to the transboundary movement?  11. Did the notifications contain complete information (at a minimum the information)  | ents of LMOs for intentional ments of export of the Party(ies) of export of mation specified in Annex I  |
| None  None  One  None  N | ents of LMOs for intentional ments of export of the Party(ies) of export of mation specified in Annex I  |
| None   | ment?  EN  Tents of LMOs for intentional ments of the Party(ies) of export of the Party in the P |

| NOT APPLICABLE YET  | EN  |
|---|---|
| Article 11 - Procedure for live ood or feed, or for process           | ving modified organisms intended for direct use as ing (LMOs-FFP)   |
| 47. Has your country adopted spec including placing on the market, of | ific law(s) or regulation(s) for decision-making regarding domestic use LMOs-FFP?   |
| No  | EN  |
| 48. Has your country established le                                   | egal requirements for the accuracy of information to be provided by the   |
| No  | EN  |
|   | mechanism to ensure that decisions regarding LMOs-FFP that may be nt will be communicated to the Parties through the BCH? |
| No  | EN  |
| 50. Has your country established a                                    | mechanism for taking decisions on the import of LMOs-FFP?   |
| No  | EN  |
| 51. Has your country indicated its r                                  | needs for financial and technical assistance and capacity-building in   |
| Yes   | EN  |
| 52. Has your country ever taken a                                     | decision on LMOs-FFP (either on import or domestic use)?  |
| No  | EN  |
| 53. How many LMOs-FFP has your o                                      | country approved to date?   |
| 54. In the current reporting period,<br>LMOs-FFP?                     | how many decisions has your country taken regarding the import of   |
|   |   |

including placing on the market, of LMOs-FFP? 56. Has your country informed the Parties through the BCH of its decision(s) regarding import, of LMOs-FFP? 57. Has your country informed the Parties through the BCH of its decision(s) regarding domestic use, including placing on the market, of LMOs-FFP within 15 days? 58. Here you may provide further details on the implementation of Article 11 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs-FFP NOT APPLICABLE YET ΕN Article 12 - Review of decision 59. Has your country established a mechanism for the review and change of a decision regarding an intentional transboundary movement of LMOs? ΕN No 60. Has your country ever received a request for a review of a decision? No ΕN 61. Has your country ever reviewed / changed a decision regarding an intentional transboundary movement of LMOs? ΕN No 62. In the current reporting period, how many decisions were reviewed and/or changed regarding an intentional transboundary movement of an LMO? ΕN None 63. Has your country informed both the notifier and the BCH of the review and/or changes in the decision? 64. Has your country informed both the notifier and the BCH of the review and changes in the decision within thirty days? 65. Has your country provided reasons to both the notifier and the BCH for the review and/or changes in the decision? 66. Here you may provide further details on the implementation of Article 12 in your country

| 67. Has your country established a system for the application of the sin  | nplified procedure regarding an  |
|---|--|
| ntentional transboundary movement of LMOs?  | ipinieu procedure reguranig un   |
| No  | EN   |
|   |  |
| 68. Has your country ever applied the simplified procedure?   |  |
| No  | EN   |
| 69. If you answered Yes to question 68, has your country informed the F<br>cases where the simplified procedure applies?  | Parties through the BCH of the   |
| 70. In the current reporting period, how many LMOs has your country a   | pplied the simplified procedure to   |
| None  | EN   |
| 71. Here you may provide further details on the implementation of Artic   | cle 13 in your country   |
|   |  |
| Article 14 - Bilateral, regional and multilateral agreeme   | ents and arrangements  |
| Article 14 - Bilateral, regional and multilateral agreeme   | ents and arrangements  |
|   | -  |
|   | -  |
| 72. Has your country entered into any bilateral, regional or multilateral  No  73. If you answered Yes to question 72, how many LMO-related collabor  | agreements or arrangements?  EN  rative bilateral/multilateral   |
| No  73. If you answered Yes to question 72, how many LMO-related collaborarrangements has your country established with other Parties/non-Parti   | agreements or arrangements?  EN  rative bilateral/multilateral es?   |
| 72. Has your country entered into any bilateral, regional or multilateral   | agreements or arrangements?  EN  Tative bilateral/multilateral es?  Parties through the BCH of the   |
| No  73. If you answered Yes to question 72, how many LMO-related collabor arrangements has your country established with other Parties/non-Parties/4. If you answered Yes to question 72, has your country informed the Fagreements or arrangements?  75. If you answered Yes to question 72, please provide a brief description agreements or arrangements entered into                                    | agreements or arrangements?  EN  Tative bilateral/multilateral es?  Parties through the BCH of the on of the scope and objective of the                        |
| No  73. If you answered Yes to question 72, how many LMO-related collabor arrangements has your country established with other Parties/non-Parties.  74. If you answered Yes to question 72, has your country informed the Pagreements or arrangements?  75. If you answered Yes to question 72, please provide a brief description agreements or arrangements entered into                                 | agreements or arrangements?  EN  Tative bilateral/multilateral es?  Parties through the BCH of the on of the scope and objective of the cle 14 in your country |
| 72. Has your country entered into any bilateral, regional or multilateral  No  73. If you answered Yes to question 72, how many LMO-related collabor arrangements has your country established with other Parties/non-Parti  74. If you answered Yes to question 72, has your country informed the Fagreements or arrangements?  75. If you answered Yes to question 72, please provide a brief description | agreements or arrangements?  EN  Tative bilateral/multilateral es?  Parties through the BCH of the on of the scope and objective of the cle 14 in your country |

| The National Structure is being set up. At the moment, the Country already has a sma working group that will later conduct this National Structure.                              | " EN     |
|--|----------|
| 78. If you answered Yes to question 77, does this framework include procedures for identifying training national experts to conduct risk assessments?                            | and/or   |
| No   | EN       |
| 79 a. How many people in your country have been trained in risk assessment, monitoring, man and control of LMOs? Risk assessment:  | agement  |
| None   | EN       |
| 79 b. How many people in your country have been trained in risk assessment, monitoring, man and control of LMOs? Management / Control:   | agement  |
| None   | EN       |
| 79 c. How many people in your country have been trained in risk assessment, monitoring, man and control of LMOs? Monitoring:   | agement  |
| None   | EN       |
| 30. Is your country using training material and/or technical guidance for training in risk assessnisk management of LMOs?  | nent and |
| No   | EN       |
| 31. Is your country using the "ManualonRiskAssessmentofLMOs" (developed by CBD Secretaria raining in risk assessment?  | t) for   |
| No   | EN       |
| 32. Is your country using the "GuidanceonRiskAssessmentofLMOs" (developed by the Online Fo<br>the AHTEG on Risk Assessment and Risk Management) for training in risk assessment? | rum and  |
| No   | EN       |
| 33. Are the currently available training materials or technical guidance on risk assessment and, management of LMOs sufficient?  | /or risk |
| No   | EN       |

| biological diversity, taking into account risks to human health? Detect:   |   |
|--|---|
| No   | EN  |
| 84 b. Does your country have the capacity to detect, identify, assess and, organisms or specific traits that may have adverse effects on the conserv biological diversity, taking into account risks to human health? Identify:  | _   |
| No   | EN  |
| 84 c. Does your country have the capacity to detect, identify, assess and/<br>organisms or specific traits that may have adverse effects on the conserv<br>piological diversity, taking into account risks to human health? Assess:  | _   |
| No   | EN  |
| 34 d. Does your country have the capacity to detect, identify, assess and, organisms or specific traits that may have adverse effects on the conservolological diversity, taking into account risks to human health? Monitor:  |   |
| No   | EN  |
|  | LIV   |
| assessment or risk management, or for evaluating risk assessment report  | purpose of conducting risk  |
| assessment or risk management, or for evaluating risk assessment report  | purpose of conducting risk  |
| Assessment or risk management, or for evaluating risk assessment report assessment:  No  B5 b. Has your country adopted or used any guidance documents for the assessment or risk management, or for evaluating risk assessment report   | purpose of conducting risk ts submitted by notifiers? Risk  EN  purpose of conducting risk  |
| Assessment or risk management, or for evaluating risk assessment report assessment:  No  35 b. Has your country adopted or used any guidance documents for the assessment or risk management, or for evaluating risk assessment report   | purpose of conducting risk ts submitted by notifiers? Risk  EN  purpose of conducting risk  |
| No  Solution is a sessment or risk management, or for evaluating risk assessment report assessment:  No  Solution is a sessment or risk management, or used any guidance documents for the assessment or risk management, or for evaluating risk assessment report management:  No  Solution is a sessment or risk management or for evaluating risk assessment report management:  No  Solution is a sessment or risk management or for evaluating risk assessment report management:  No | purpose of conducting risk ts submitted by notifiers? Risk  EN  purpose of conducting risk ts submitted by notifiers? Risk  EN  oped by the Online Forum and k assessment or risk         |
| No  Solution is a sessment or risk management, or for evaluating risk assessment report assessment:  No  Solution is a sessment or risk management, or used any guidance documents for the assessment or risk management, or for evaluating risk assessment report management:  No  Solution is a sessment or risk management or for evaluating risk assessment report management:  No  Solution is a sessment or risk management or for evaluating risk assessment report management:  No | purpose of conducting risk ts submitted by notifiers? Risk  EN  purpose of conducting risk ts submitted by notifiers? Risk  EN  oped by the Online Forum and k assessment or risk         |
| 85 b. Has your country adopted or used any guidance documents for the assessment or risk management, or for evaluating risk assessment report management:  No  86. Is your country using the "GuidanceonRiskAssessmentofLMOs" (developed the AHTEG on Risk Assessment and Risk Management) for conducting risk management, or for evaluating risk assessment reports submitted by not  | purpose of conducting risk ts submitted by notifiers? Risk  EN  purpose of conducting risk ts submitted by notifiers? Risk  EN  oped by the Online Forum and k assessment or risk ifiers? |

| Yes  | EN                       |
|--|--------------------------|
| 39. Has your country ever conducted a risk assessment of an LMO including any to LMOs, e.g. for contained use, field trials, commercial purposes, direct use as for processing?                            |                          |
| No   | EN                       |
| 90. If you answered Yes to question 89, please indicate the scope of the risk asses  | ssments (select all that |
| 91. If you answered Yes to question 89, were the summary reports of the risk assented the BCH?   | essments submitted to    |
| 22. If you answered Yes to question 89, were risk assessments conducted for all defor intentional introduction into the environment or on domestic use of LMOs for dor for processing?                     |                          |
| 93. If you answered Yes to question 89, how many risk assessments were conduct reporting period?   | ed in the current        |
| 94. Has your country taken measures to ensure that any LMO, whether imported oundergoes an appropriate period of observation that is commensurate with its life time before it is put to its intended use? |                          |
| No   | EN                       |
| 95. Has your country established a mechanism for monitoring potential effects of nto the environment?  | LMOs that are released   |
| No   | EN                       |
| 96. Does your country have the infrastructure (e.g. laboratory facilities) for monito  | oring or managing        |
| No   | EN                       |
| 97. Here you may provide further details on the implementation of Articles 15 and  | d 16 in vour country     |

98. Has your country established and maintained appropriate measures to prevent unintentional transboundary movements of LMOs? ΕN No 99. Has your country established a mechanism for addressing emergency measures in case of unintentional transboundary movements of LMOs that are likely to have significant adverse effect on biological diversity? ΕN No 100. Does your country have the capacity to take appropriate measures in the event that an LMO is unintentionally released? No ΕN 101. In the current reporting period, how many times has your country received information concerning occurrences that led, or may have led, to unintentional transboundary movement(s) of one or more LMOs to or from territories under its jurisdiction? ΕN Never 102. If you answered Yes to question 101, has your country notified affected or potentially affected States, the BCH and, where appropriate, relevant international organizations, of the above release? 103. If you answered Yes to question 101, who did your country notify? 104. If you answered Yes to question 101, has your country immediately consulted the affected or potentially affected States to enable them to determine appropriate responses and initiate necessary action, including emergency measures? 105. Here you may provide further details on the implementation of Article 17 in your country Article 18 - Handling, transport, packaging and identification 106. Has your country taken measures to require that LMOs that are subject to transboundary movement are handled, packaged and transported under conditions of safety, taking into account relevant international rules and standards? ΕN Yes, to some extent Additional Information THERE ARE A PROJECT IN COURSE ΕN

|  | ation?   |
|--|--|
| Yes, to some extent  | EN   |
| Additional Information   |  |
| THERE ARE A PROJECT IN COURSE  | EN   |
| 108. Has your country taken measures to require that documentation accomparidentifies that, in cases where the identity of the LMOs is known through mean preservation systems, they contain living modified organisms and are not interintroduction into the environment, as well as a contact point for further inform   | s such as identity   |
| Yes, to some extent  | EN   |
| Additional Information   |  |
| THERE ARE A PROJECT IN COURSE  | EN   |
| 109. If you answered Yes or Yes, to some extent to question(s) 107 and/or 108, documentation does your country require for the identification of LMOs-FFP?   | , what type of   |
| Existing types of documentation  | EN   |
| 110. Has your country taken measures to require that documentation accompa   |  |
| requirements for the safe handling, storage, transport and use, the contact po   | int for further information,   |
| requirements for the safe handling, storage, transport and use, the contact po   | int for further information,   |
| destined for contained use clearly identifies them as living modified organisms requirements for the safe handling, storage, transport and use, the contact poincluding the name and address of the individual and institution to whom the Linear No.  111. If you answered Yes or Yes, to some extent to question 110, what type of country require for the identification of LMOs that are destined for contained? | int for further information, .MO are consigned?  |
| requirements for the safe handling, storage, transport and use, the contact po including the name and address of the individual and institution to whom the L  No  111. If you answered Yes or Yes, to some extent to question 110, what type of   | int for further information, MO are consigned?  EN  documentation does your anying LMOs that are racteristics, any int for further information contains a declaration that |

| 114. Does your country have available any guidance for the purpose of ensuring the safe handling transport, and packaging of living modified organisms?   |        |
|---|--------|
| No  | EN     |
| 115. Does your country have the capacity to enforce the requirements of identification and document   | entati |
| No  | EN     |
| 116. How many customs officers in your country have received training in the identification of LMC  | s?     |
| None  | EN     |
| 117. Has your country established procedures for the sampling and detection of LMOs?  |        |
| No  | EN     |
| 118. How many laboratory personnel in your country have received training in detection of LMOs?   |        |
| None  | EN     |
| 119. Does your country have reliable access to laboratory facilities for the detection of LMOs?   |        |
| No  | EN     |
| 120. How many laboratories in your country are certified for LMO detection?   |        |
| None  | EN     |
| 121. How many of the certified laboratories in the previous question are currently operating in the detection of LMOs?  |        |
| 122. Here you may provide further details on the implementation of Article 18 in your country:  |        |
| In the next report we will have more updates on this article, at that moment we are implementing a project to train technicians and train laboratories in detecting LMOs. Then, in the following period, we will have completed the training. | EN     |

123. In case your country has designated more than one competent national authority, has your country established a mechanism for the coordination of their actions prior to taking decisions regarding LMOs? EN n/a 124. Has your country established adequate institutional capacity to enable the competent national authority(ies) to perform the administrative functions required by the Cartagena Protocol on Biosafety? ΕN Yes, to some extent Additional Information ΕN The appropriate creation of conditions is in process 125. Here you may provide further details on the implementation of Article 19 in your country Article 20 - Information Sharing and the Biosafety Clearing-House (BCH) 126 a. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Existing national legislation, regulations and guidelines for implementing the Protocol, as well as information required by Parties for the advance informed agreement procedure (Article 20, paragraph 3 (a)) Information available but not in the BCH ΕN 126 b. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. National laws, regulations and guidelines applicable to the import of LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 5) Information available but only partially available in the BCH ΕN 126 c. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Bilateral, multilateral and regional agreements and arrangements (Articles 14, paragraph 2 and 20, paragraph 3 (b)) Information not available ΕN 126 d. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Contact details for competent national authorities (Article 19, paragraphs 2 and 3), national focal points (Article 19, paragraphs 1 and 3), and emergency contacts (Article 17, paragraph 3 (e))

#### Information available but not in the BCH

ΕN

126 e. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Reports submitted by the Parties on the operation of the Protocol (Article 20, paragraph 3 (e))

Information available but only partially available in the BCH

ΕN

126 f. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Decisions by a Party on regulating the transit of specific living modified organisms (LMOs) (Article 6, paragraph 1)

Information not available

ΕN

126 g. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Occurrence of unintentional transboundary movements that are likely to have significant adverse effects on biological diversity (Article 17, paragraph 1)

Information not available

ΕN

126 h. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Illegal transboundary movements of LMOs (Article 25, paragraph 3)

Information not available

ΕN

126 i. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Final decisions regarding the importation or release of LMOs (i.e. approval or prohibition, any conditions, requests for further information, extensions granted, reasons for decision) (Articles 10, paragraph 3 and 20, paragraph 3(d))

Information not available

ΕN

126 j. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Information on the application of domestic regulations to specific imports of LMOs (Article 14, paragraph 4)

Information not available

ΕN

126 k. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Final decisions regarding the domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing (Article 11, paragraph 1)

#### Information not available

ΕN

126 I. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Final decisions regarding the import of LMOs intended for direct use as food or feed, or for processing that are taken under domestic regulatory frameworks (Article 11, paragraph 4) or in accordance with annex III (Article 11, paragraph 6) (requirement of Article 20, paragraph 3(d))

#### Information not available

ΕN

126 m. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Declarations regarding the framework to be used for LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 6)

#### Information not available

ΕN

126 n. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Review and change of decisions regarding intentional transboundary movements of LMOs (Article 12, paragraph 1)

#### Information not available

ΕN

126 o. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. LMOs granted exemption status by each Party (Article 13, paragraph 1)

#### Information not available

ΕN

126 p. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Cases where intentional transboundary movement may take place at the same time as the movement is notified to the Party of import (Article 13, paragraph 1)

#### Information not available

ΕN

126 q. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Summaries of risk assessments or environmental reviews of LMOs generated by

|  | EN          |
|--|-------------|
|  |             |
| 127. Has your country established a mechanism for strengthening the capacity of the BCH Nationa<br>Point to perform its administrative functions?  | al Foca     |
| Yes, to some extent  | EN          |
| Additional Information   |             |
| HAS A PROJECT ON TRAINING FOR THE USE OF THE BCH PLATFORM PROGRAMMED TO START IN the NEXTS YEARS   | EN          |
| 128. Has your country established a mechanism for the coordination among the BCH National Foca<br>the Cartagena Protocol focal point, and the competent national authority(ies) for making informati<br>available to the BCH?  |             |
| No   | EN          |
| 129. Does your country use the information available in the BCH in its decision making processes of LMOs?  | on          |
| n/a  | EN          |
|  |             |
| 130. Has your country experienced difficulties accessing or using the BCH?   |             |
| 130. Has your country experienced difficulties accessing or using the BCH?  Yes  | EN          |
|  | EN          |
| Yes  | EN          |
| Yes  Additional Information  Until now it was an unknown tool in terms of management, but we are already working   |             |
| Yes  Additional Information  Until now it was an unknown tool in terms of management, but we are already working on training, in the next report it will already be part of our work tools.  |             |
| Yes  Additional Information  Until now it was an unknown tool in terms of management, but we are already working on training, in the next report it will already be part of our work tools.  131. Is the information submitted by your country to the BCH complete and up-to date?   | EN EN       |
| Yes  Additional Information  Until now it was an unknown tool in terms of management, but we are already working on training, in the next report it will already be part of our work tools.  131. Is the information submitted by your country to the BCH complete and up-to date?  No  132. Please indicate the number of regional, national and international events organized in relation   | EN EN       |
| Yes  Additional Information  Until now it was an unknown tool in terms of management, but we are already working on training, in the next report it will already be part of our work tools.  131. Is the information submitted by your country to the BCH complete and up-to date?  No  132. Please indicate the number of regional, national and international events organized in relation biosafety (e.g. seminars, workshops, press conferences, educational events, etc.,) in the last 2 years. | EN EN EN EN |

| National website   |   |
|--|---|
| .35. Here you may provide further details on the implementa  | tion of Article 20 in your country  |
| rticle 21 - Confidential information   |   |
| .36. Has your country established procedures to protect confi<br>rotocol?  | dential information received under the  |
| Yes  | EN  |
| 37. Does your country allow the notifier to identify information   | on that is to be treated as confidential?   |
| No   | EN  |
|  |   |
| rticle 22 - Capacity-building  .39. Does your country have predictable and reliable funding  |   |
| rticle 22 - Capacity-building  39. Does your country have predictable and reliable funding   |   |
| rticle 22 - Capacity-building  39. Does your country have predictable and reliable funding implementation of the Protocol?  Yes  40. Has your country received external support or benefited farties in the development and/or strengthening of human research.  | for building capacity for the effective  EN  from collaborative activities with other   |
| Trticle 22 - Capacity-building  139. Does your country have predictable and reliable funding implementation of the Protocol?  Yes  140. Has your country received external support or benefited Parties in the development and/or strengthening of human reserved.   | for building capacity for the effective  EN  from collaborative activities with other   |
| 140. Has your country received external support or benefited Parties in the development and/or strengthening of human responses fety?  | for building capacity for the effective  EN  from collaborative activities with other sources and institutional capacities in                                 |
| rticle 22 - Capacity-building  1.39. Does your country have predictable and reliable funding implementation of the Protocol?  Yes  1.40. Has your country received external support or benefited Parties in the development and/or strengthening of human respiosafety?  Yes   | for building capacity for the effective  EN  from collaborative activities with other sources and institutional capacities in                                 |
| rticle 22 - Capacity-building  139. Does your country have predictable and reliable funding implementation of the Protocol?  Yes  140. Has your country received external support or benefited Parties in the development and/or strengthening of human respiosafety?  Yes  141. If you answered Yes to question 140, how were these respins the development and the protocological strengths are protocological strengths are protocological strengths are protocological strengths and the protocological strengths are protocological strengths are protocological strengths and the protocological strengths are protocological strengths are protocological strengths. | for building capacity for the effective  EN  from collaborative activities with other sources and institutional capacities in  EN  ources made available?  EN |

| Yes  | EN   |
|--|--|
| 145. If you answered Yes to question 144, how would you characterize the pro   | ocess?                                     |
| Easy   | EN   |
| 146. Has your country ever received funding from the GEF for building capaci   | ty in biosafety?                           |
| Pilot Biosafety Enabling Activity Building Capacity for Effective Participation in the BCH (Phase II)  |  |
| 147. During the current reporting period, has your country undertaken activition strengthening of human resources and institutional capacities in biosafety?   | ·  |
| Yes  | EN   |
|  |  |
|  | e these activities                         |
|  | e these activities                         |
| Human resources capacity development and training Public awareness, participation and education in biosafety  149. During the current reporting period, has your country carried out a capacity  |  |
| Human resources capacity development and training Public awareness, participation and education in biosafety  149. During the current reporting period, has your country carried out a capacity  |  |
| Public awareness, participation and education in biosafety  149. During the current reporting period, has your country carried out a capacassessment?  | city-building needs                        |
| Human resources capacity development and training Public awareness, participation and education in biosafety  149. During the current reporting period, has your country carried out a capacassessment?  Yes   | city-building needs                        |
| Human resources capacity development and training Public awareness, participation and education in biosafety  149. During the current reporting period, has your country carried out a capaciessessment?  Yes  150. If you answered Yes to question 149, has this information been submitted   | city-building needs  EN  d to the BCH?     |
| Human resources capacity development and training Public awareness, participation and education in biosafety  149. During the current reporting period, has your country carried out a capacassessment?  Yes  150. If you answered Yes to question 149, has this information been submitted  No  | city-building needs  EN  d to the BCH?     |
| Human resources capacity development and training Public awareness, participation and education in biosafety  149. During the current reporting period, has your country carried out a capaciassessment?  Yes  150. If you answered Yes to question 149, has this information been submitted  No  151. Does your country still have capacity-building needs? | city-building needs  EN  d to the BCH?  EN |

Risk management

Scientific, technical and institutional collaboration at subregional, regional and international levels

Technology transfer

Identification of LMOs, including their detection

Implementation of the documentation requirements under Article 18.2 of the Protocol Handling of confidential information

Measures to address unintentional and/or illegal transboundary movements of LMOs Scientific biosafety research relating to LMOs

Taking into account risks to human health

| 153. Has your coun | try developed a | capacity-building | strategy or | action plan? |
|--------------------|-----------------|-------------------|-------------|--------------|
|--------------------|-----------------|-------------------|-------------|--------------|

No

ΕN

154. Does your country have in place a functional national mechanism for coordinating biosafety capacity-building initiatives?

Yes

ΕN

155. How many biosafety short-term training programmes and/or academic courses are offered annually in your country?

None

ΕN

156. Has your country submitted the details of national biosafety experts to the Roster of Experts in the BCH?

No

ΕN

157. Here you may provide further details on the implementation of Article 22 in your country, including further details about your experience in accessing GEF funds

#### Article 23 - Public awareness and participation

158. Has your country established a strategy or put in place legislation for promoting and facilitating public awareness, education and participation concerning the safe transfer, handling and use of LMOs?

Yes, to some extent

ΕN

Additional Information

THERE ARE A PROJECT IN COURSE


ΕN

| Yes  | EN                        |
|--|---------------------------|
| .60. Does your country have any awareness and outreach programmes on biosaf  | fety?                     |
| Yes  | EN                        |
| .61. If you answered Yes to question 160, please indicate what entity is responsib<br>programmes and/or services and at which level the programmes take place (e.g.    |                           |
| MINISTRY OF ENVIRONMENT  | EN                        |
| .62. Has your country established a biosafety website searchable archives, nation ections in existing national libraries dedicated to biosafety educational materials  |                           |
| No   | EN                        |
| .63. How many collaborative initiatives (including joint activities) on the Cartager<br>Conventions and processes has your government established in the last 4 years? |                           |
| One or more  | EN                        |
| .64. Has your country established a mechanism to ensure public access to informorganisms that may be imported?   | nation on living modified |
| No   | EN                        |
| .65. Has your country established a mechanism to consult the public in the decis   | sion-making process       |
| No   | EN                        |
| .66. Has your country established a mechanism to make available to the public t<br>aken on LMOs?   | he results of decisions   |
| No   | EN                        |
| .67. Has your country informed the public about existing modalities for public pa  | rticipation in the        |
| lecision-making process regarding living modified organisms?   |                           |

| 170. Has your country taken any initiative to inform its public about the   | e means of public access to the     |
|---|-------------------------------------|
| Biosafety Clearing-House?  No   | EN                                  |
| 171. How many academic institutions in your country are offering biosaccourses and programmes?  | afety education and training        |
| None  | EN                                  |
| 172. Please indicate the number of educational materials and/or online available and accessible to the public in your country:                | modules on biosafety that are       |
| None  | EN                                  |
| 173. In the current reporting period, has your country promoted and fa education and participation concerning the safe transfer, handling and |                                     |
| No  | EN                                  |
| 174. If you answered Yes to question 173, has your country cooperated bodies?   | l with other States and internation |
| 175. In the current reporting period, how many times has your country decision-making process regarding LMOs and made the results of such     | •                                   |
| Never   | EN                                  |
| 176. Here you may provide further details on the implementation of Ar   | ticle 23 in your country            |
| Article 24 - Non-Parties  |                                     |
| 177. Has your country entered into any bilateral, regional, or multilater regarding transboundary movements of LMOs?                          | ral agreement with non-Parties      |
| No  | EN                                  |
| 178. Has your country ever imported LMOs from a non-Party?  |                                     |
| No  | EN                                  |

| No  | EN   |
|---|--|
| 180. If you answered Yes to questions 178 or 179, were the transboundary move with the objective of the Cartagena Protocol on Biosafety?  | ments of LMOs consister  |
| L81. If you answered Yes to questions 178 or 179, was information about these to submitted to the BCH?  | ransboundary movemen   |
| 182. If your country is not a Party to the Cartagena Protocol, has it contributed in MOs released in, or moved into, or out of, areas within its national jurisdiction?   | formation to the BCH on  |
| 183. Here you may provide further details on the implementation of Article 24 in  | your country:  |
| rticle 25 - Illegal transboundary movements   |  |
| L84. Has your country adopted domestic measures aimed at preventing and/or p  |  |
| No  | EN   |
|   |  |
| 185. Has your country established a strategy for detecting illegal transboundary  | movements of LMOs?   |
| No  | movements of LMOs?   |
| No 186. In the current reporting period, how many times has your country received in  | nformation concerning  |
| No 186. In the current reporting period, how many times has your country received in  | nformation concerning  |
| 186. In the current reporting period, how many times has your country received i<br>cases of illegal transboundary movements of an LMO to or from territories under   | nformation concerning its jurisdiction?  EN  |
| No  186. In the current reporting period, how many times has your country received is cases of illegal transboundary movements of an LMO to or from territories under Never  187. If your country received information concerning cases of illegal transboundary  | nformation concerning its jurisdiction?  EN  ary movements of an LM Party(ies) involved?                               |
| No  1.86. In the current reporting period, how many times has your country received it cases of illegal transboundary movements of an LMO to or from territories under Never  1.87. If your country received information concerning cases of illegal transboundarn the current reporting period, has your country informed the BCH and the other 1.88. If your country received information concerning cases of illegal transboundary | nformation concerning its jurisdiction?  EN  Ary movements of an LM Party(ies) involved?  Ary movements of an LM O(s)? |

191. Here you may provide further details on the implementation of Article 25 in your country **Article 26 - Socio-economic considerations** 192. Does your country have any specific approaches or requirements that facilitate how socio-economic considerations should be taken into account in LMO decision making? No ΕN 193. If your country has taken a decision on import, has it ever taken into account socio-economic considerations arising from the impact of the LMO on the conservation and sustainable use of biological diversity? ΕN Not applicable 194. How many peer-reviewed published materials has your country used for the purpose of elaborating or determining national actions with regard to socio-economic considerations? ΕN None 195. What is your country's experience, if any, in taking socio-economic considerations into account in LMO decision making? Please give details: 196. Has your country cooperated with other Parties on research and information exchange on any socioeconomic impacts of LMOs? ΕN No 197. Here you may provide further details on the implementation of Article 26 in your country **Article 27 - Liability and Redress** 198. Has your country ratified or acceded to the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress? ΕN No 199. If you answered No to question 198, is there any national process in place towards becoming a Party? Yes ΕN 200. Has your country received any financial and/or technical assistance for capacity-building in the area of liability and redress relating to living modified organisms?



### **Comments on reporting format**

208. Please use this field to provide any other information on difficulties that you have encountered in filling in this report

BCH-NR3-AO-115705-2

# **Further Information**

Questions about the Cartagena Protocol on Biosafety or the operation of the Biosafety Clearing-House may be directed to the Secretariat of the Convention on Biological Diversity.

Secretariat of the Convention on Biological Diversity

413 rue Saint-Jacques, suite 800 Montreal, Québec, H2Y 1N9 Canada

Fax: +1 514 288-6588 Email: secretariat@cbd.int